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Imaging techniques based on retinal autoﬂuorescence have found broad applications in ophthalmology
because they are extremely sensitive and noninvasive. Conventional fundus autoﬂuorescence imaging
measures ﬂuorescence intensity of endogenous retinal ﬂuorophores. It mainly derives its signal from
lipofuscin at the level of the retinal pigment epithelium. Fundus autoﬂuorescence, however, can not only
be characterized by the spatial distribution of the ﬂuorescence intensity or emission spectrum, but also
by a characteristic ﬂuorescence lifetime function. The ﬂuorescence lifetime is the average amount of time
a ﬂuorophore remains in the excited state following excitation. Fluorescence lifetime imaging ophthal-
moscopy (FLIO) is an emerging imaging modality for in vivo measurement of lifetimes of endogenous
retinal ﬂuorophores. Recent reports in this ﬁeld have contributed to our understanding of the patho-
physiology of various macular and retinal diseases.
Within this review, the basic concept of ﬂuorescence lifetime imaging is provided. It includes technical
background information and correlation with in vitro measurements of individual retinal metabolites. In
a second part, clinical applications of ﬂuorescence lifetime imaging and ﬂuorescence lifetime features of
selected retinal diseases such as Stargardt disease, age-related macular degeneration, choroideremia,
central serous chorioretinopathy, macular holes, diabetic retinopathy, and retinal artery occlusion are
discussed. Potential areas of use for ﬂuorescence lifetime imaging ophthalmoscopy will be outlined at the
end of this review.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Fluorescence lifetime imaging ophthalmoscopy (FLIO) is a rela-
tively new method within the ﬁeld of retinal imaging. It is a non-
invasive technique to measure and quantify lifetimes of endoge-
nous retinal autoﬂuorescence. When endogenous ﬂuorophores are
excited by photons derived from a monochromatic light source,
they gain a higher level of energy before returning to their ground
state by emitting photons of longer wavelengths than the exciting
light. The average time between excitation and reaching the ground
state again can be quantiﬁed as the ﬂuorescence lifetime.
The technique is based on ﬂuorescence lifetime imaging mi-
croscopy (FLIM) which is used in basic science for analysis of
microscopic images of ﬁxed, as well as living cells (Ishikawa-
Ankerhold et al., 2012). Every single ﬂuorophore is characterized
by its own excitation and emission wavelength spectrum and ex-
hibits an individual ﬂuorescence lifetime. The ﬂuorescence life-
times depend on the molecular environment but are largely
independent of the ﬂuorophore's concentration (Becker, 2012).
Therefore, ﬂuorescence lifetime measurement can be applied to
detect weakly ﬂuorescing ﬂuorophores if they differ in terms of
their lifetime. Additionally, lifetimes can be used as indicator for
speciﬁc metabolic conditions of changes within the molecular
micro-environment (Becker, 2012).
Fundus autoﬂuorescence intensity imaging and FLIO are two
very closely related imaging modalities and thereby share many
common facets. Whereas conventional fundus autoﬂuorescence
measurement provides spacial resolved information on ﬂuores-
cence intensities, (Delori, 1994; von Rückmann et al., 1995a,b) FLIO
additionally measures ﬂuorescence lifetimes or decay times and
thereby includes time as a third dimension (space and time
resolved). This additional dimension enables extracting many
components that have overlapping emission properties.
Retinal autoﬂuorescence intensity predominantly stems from
lipofuscin which is located within the lysosomes of the retinalpigment epithelium (RPE) (Delori et al., 1995). Accumulation of
lipofuscin is a hallmark of aging RPE cells originating from
incomplete degradation of photoreceptor outer segment disks
(Delori et al., 1995; Bertolotto et al., 2014). Major constituents of
RPE lipofuscin are a complex mixture of di-retinal conjugates, one
of which is A2E (Sparrow et al., 2003; Sparrow et al., 2012).
Extracellular ﬂuorophores from shed outer segment debris in the
subretinal space as well as extracellular proteins also contain
components from di-retinal adducts.
Additionally, melanin has been reported to have a peak excita-
tionwavelength of 450 nmwith a peak emission starting at 440 nm
extending to the near-infrared spectra (>800 nm). Therefore,
melanin is likely to contribute to ﬂuorescence lifetime measure-
ments with FLIO (Gallas and Eisner, 1987; K€onig, 2008) (Kayatz
et al., 2001; Keilhauer and Delori, 2006; Han et al., 2009; Yung
et al., 2016). However, given the major contribution of lipofuscin
to the autoﬂuorescence signal, it is difﬁcult to identify weaker
endogenous ﬂuorophores using autoﬂuorescence intensity mea-
surement in the retina. Because ﬂuorescence lifetimes are largely
independent of the ﬂuorophores concentration and intensity, the
predominance of lipofuscin can be overcome with FLIO, and ﬂuo-
rophores other than lipofuscin can be identiﬁed by their lifetimes.
In this review, we will provide an overview of the fundamentals
of autoﬂuorescence lifetime imaging and the technical principles of
FLIO. Furthermore, we will provide a summary of ﬁndings from
FLIO measurements in healthy retinae as well as in various retinal
diseases, and highlight the potential beneﬁt and further perspec-
tives of this technique.2. Fundamentals of autoﬂuorescence lifetime imaging of the
retina
2.1. Historical background
Although ﬂuorescence lifetimemeasurement is considered to be
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Achilefu for review (Berezin and Achilefu, 2010)), it has been
initially described in the 19th century. In 1859, Edmond Bequerel
developed the so called phosphoroscope with a time resolution of
104 s. In the 1920s, time resolution was improved to 108 s which
enabled the ﬁrst ﬂuorescence lifetime measurements (Gottling,
1923; Gaviola, 1926). However, only the advent of short pulse la-
sers and the introduction of time-correlated single photon counting
(TCSPC) (Lewis et al., 1973; Leskovar et al., 1976) made ﬂuorescence
lifetime measurement sufﬁciently sensitive for the detection of
intrinsic ﬂuorophores in living tissue.
Schweitzer et al. ﬁrst applied lifetime imaging to the human
retina in vivo (Schweitzer et al., 2001a,b). They ﬁber-coupled a
mode-locked argon-ion laser into a scanning laser ophthalmoscope
(cLSO, Carl Zeiss, Jena, Germany) and used TCSPC for ﬂuorescence
detection. However, the lack of an image registration algorithm
limited the time available for the recording of an image without
motion artifacts to few seconds. This resulted in the recording of
some hundred photons per pixel only. Despite the resulting low
signal to noise ratio, ﬁrst ﬂuorescence lifetime images were recor-
ded in 2001 (Schweitzer et al., 2001a,b). An ofﬂine registration of
recorded images was introduced in 2002 (Schweitzer et al., 2002)
and ﬁrst clinical experiments in patients with age-related macular
degeneration (AMD) were published in 2003 using a picosecond
diode laser as light source (Schweitzer et al., 2003). Although the
resolution was still low due to limited memory of the TCSPC elec-
tronics (64  64 pixels with a size of 80  80 mm2), the images
clearly revealed an extension of lifetimes in age-related macular
degeneration (Schweitzer et al., 2004). In vitro and histological
studies were performed to identify the ﬂuorophores seen in fundus
autoﬂuorescence and to measure their emission spectra as well as
lifetimes (Schweitzer et al., 2007a; Schweitzer et al., 2007b).
Considerable progress was made with the use of the Heidelberg
Retina Angiograph scanner [Heidelberg Engineering, Heidelberg,
Germany] enabling an online image registration (Hammer et al.,
2009). An industrially designed prototype device, based on the
Heidelberg Engineering Spectralis scanner, was ﬁrst used by Dysli
et al. (Dysli et al., 2014b). More recent clinical research with this
device is described in later sections of this review.
2.2. Fluorescence lifetime imaging microscopy fundamentals
Fluorescence lifetime microscopy (FLIM) adds a number of
beneﬁts to traditional ﬂuorescence-based imaging. Largely sharing
the same microscope, FLIM attachments provide complementary
contrast to biological tissue, present a snapshot of the environment
around the endogenous or exogenous ﬂuorophore, and reduce the
background associated with typical ﬂuorescence imaging. With
FLIM, many hidden details of cell or tissue architecture can be
exposed, and their machinery can be investigated in greater detail.
A conventional FLIM microscope system operates in the visible and
near infrared (NIR) range (400e900 nm) with some of the latest
developments going as far as deep ultraviolet (UV, 240 nm) (De
Jong et al., 2015) and shortwave infrared (1700 nm) wavelengths
(Becker and Shcheslavsky, 2016). With such a broad spectral range,
FLIM can efﬁciently excite endogenous ﬂuorophores found in the
retina and surrounding tissue, such as elastin, collagen, and
melanin, as well as many exogenous probes, providing valuable
intrinsic structural and biochemical information. However, strong
absorption of UV by UV-B and UV-A ﬁlter molecules present in the
human lens and cornea precludes the usage of UV light sources for
retinal imaging (Tsentalovich et al., 2011). In addition, because of
the damaging potential of the UV and mid-infrared light to the
retina, such wavelengths of excitation are unlikely to ﬁnd appli-
cations in clinics. The current ﬂuorescence lifetime imagingophthalmoscopy technique relies on 473 nm lasers. However, the
method is not restricted to a speciﬁc wavelength.
Single-photon excitation for the majority of ﬂuorophores found
in the retina lies primarily in the ultraviolet range, and their ﬂuo-
rescence cannot be excited non-invasively through the pupil of the
eye because of the ocular transmission window (Palczewska et al.,
2014; Sharma et al., 2016). As mentioned above, this window re-
stricts the UV and deep-blue photons from reaching the retina.
Interestingly, the spectral transparency is different across the spe-
cies. Thus, the anterior segment of the primate eye transmits light
only at the wavelengths longer than 400 nm, while rabbit's eye
transmits photons down to 350 nm and rats' eye transmits as lowas
300 nm (Dillon et al., 2000). With an advance of two-photon
excitation techniques this is no longer a limitation (Sharma et al.,
2013; Palczewska et al., 2014; Sharma et al., 2016) and the ret-
ina's ﬂuorophores can be directly excited with red or near-infrared
light. Given that the ﬂuorescence lifetime is independent on the
method of excitation, in vivo retinal imaging with two-photon
excitation, although not reported yet, is expected to provide the
same lifetime results as with a single photon excitation.
2.2.1. Theory of ﬂuorescence lifetime
The ﬂuorescence of organic molecules used in FLIM corresponds
to the excitation of the light absorbing molecule from its ground
state or singlet state S0 to one of the excited states (S1, S2 etc.) and
subsequent radiative transition from the lowest energy level at the
ﬁrst singlet state S1 back to the ground singlet state S0 (Fig. 1) This
S1 to S0 transition is characterized by several quantitative param-
eters: i) ﬂuorescence spectrum I(l), deﬁned as ﬂuorescence in-
tensity as a function of a wavelength, ii) quantum yield Ф, the ratio
of the total number of emitted photons per number of absorbed
photons, and iii) ﬂuorescence lifetime T e the average time the
excited molecule spends in the excited state. While measured
independently, all three parameters are related. Typically, an
organic ﬂuorophore with strong ﬂuorescence intensity demon-
strates a high quantum yield and a relatively long ﬂuorescence
lifetime. Of these three parameters, ﬂuorescence lifetime is the
most valuable for imaging as it combines the intensity of the
ﬂuorescence signal and the change in time during the decay pro-
cess. The time of decay is highly sensitive to the environment and
constitutes the quintessence of ﬂuorescence lifetime imaging.
Most of organic ﬂuorophores, both endogenous and exogenous,
including ﬂuorescent proteins, decay within several nanoseconds
(Berezin and Achilefu, 2010). On a molecular timescale, ﬂuores-
cence lifetime is a relatively slow process. During this time, a high
energy ﬂuorophore can undergo a variety of transformations, from
minor electron redistribution to structural isomerization and
chemical reaction with surrounding molecules. Under ideal con-
ditions, (i.e. a vacuumwith no other molecules around) the excited
state has the longest lifetime, known as the natural ﬂuorescence
lifetime Tn. This value is difﬁcult to measure, but possible to predict
using the well-known and historically important Strickler-Berg
equation (Strickler and Berg, 1962). Any activity or process
around the ﬂuorophore (solvation, heating, collisions with
quenchers) will absorb energy form the ﬂuorophore while it is still
in the excited state, and lead to a decrease in ﬂuorescence lifetime.
Thus, mapping the ﬂuorescence lifetime of a ﬂuorophore in a cell or
a tissue is essentially mapping the biochemical processes occurring
in the vicinity of the ﬂuorophore during decay.
2.2.2. Data acquisition
A number of great advances in instrumentation havemade FLIM
systems highly ﬂexible with a variety of detectors and light sources
capable of achieving rapid imaging under low light conditions
necessary to preserve biological samples (Suhling et al., 2016).
Fig. 1. Energy levels and radiative transition from the excited state (S1/S2) to the
ground state (S0).
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Picoquant, Berlin, Germany; Becker&Hickl, Berlin, Germany] and
frequency-domain [e.g. ISS ﬂuorescence imaging, USA; Lambert
Instruments, Netherlands] data acquisition methods are used to
map ﬂuorescence lifetime on a microscopic level. Although the
basic hardware and data processingmethods for each technique are
different, both approaches are mathematically equivalent and their
data can be interconverted. Each method has advantages and dis-
advantages. Some FLIM microscopes implement time-domain and
frequency-domain techniques.
Point-by-point lifetime detection systems on conventional
confocal laser scanning microscopes mainly operate in the time-
domain, using time-correlated single photon counting (TCSPC)
detectors (Becker, 2005, 2008) or fast-gated image intensiﬁers
(Sparks et al., 2017). Measurement of ﬂuorescence lifetime requires
short, high intensity excitation pulses and fast detection elec-
tronics. Each point in the sample is excited sequentially with a
pulsed laser (pulse width <100 ps) at a speciﬁc excitation wave-
length. Shorter pulses improve the resolution of imaging, enable to
measure short ﬂuorescence lifetimes (Becker and Bergmann, 2003),
reduce photobleaching of the tissue chromophores (Periasamy
et al., 1996), and minimize the heat in order to prevent the tissue
from thermal damage. The time-dependent distribution of photons
emitted after each pulse is recorded at each point using photon
counting photomultiplier tubes [i.e. PMC-100-20, Becker&Hickl]
(Yazdanfar et al., 2010) or single photon avalanche photodiodes
(SPAD) (Schwartz et al., 2008) [Micro Photon Devices, Bolzano BZ,
Italy; ID Quantique, Carouge, Switzerland]. Detectors are equipped
with emission ﬁlters to eliminate stray light. Fast-gated image in-
tensiﬁers operated in time-domain measure ﬂuorescence intensity
in preset time windows after each pulse (Sparks et al., 2017). Life-
time values are derived from exponential ﬁts to the emission decay
data.
The point-by-point measurements imply relatively long acqui-
sition times that might not be optimal for wideﬁeld images, or live
tissues where a real-time rate frame is desirable. Data acquisition
can be signiﬁcantly accelerated by using a parallelized TCSPC with
an array of commercially available eight channel system single-
photon avalanche diode detectors [Becker&Hickl] (Gersbach et al.,
2010; Rech et al., 2012).
Frequency-domain is considered to be faster than TCSPC, how-
ever, it has a higher signal-to-noise ratio. In frequency-domain
systems, the incident light is sinusoidally modulated at high fre-
quencies. In this conﬁguration, emission occurs at the same fre-
quency as the incident light but experiences a phase delay (4) and achange in amplitude (M) relative to the excitation light (demodu-
lation). Data are acquired with photomultipliers or charge-coupled
devices equipped with a gain modulator. Molecules with longer
lifetimes give rise to larger phase shifts and a smaller demodulation
ratio. The key advantage of frequency-domain FLIM is its fast life-
time image acquisition, making it suitable for dynamic applications
such as live cell research (Shagaghi et al., 2017).
Most FLIM measurements (time- and frequency-domain)
employ single photon excitation. Since most biological tissues
strongly scatter light, the assignment of photons to a particular
region of the illuminated sample is challenging. In two-photon
FLIM microscopy molecules are excited by near-simultaneous ab-
sorption of two lower energy photons. This approach overcomes
the common limitation of conventional FLIM systems by restraining
ﬂuorescent signal generation to a tiny voxel at the focal point. Both,
time- and frequency-domain two-photon FLIM systems have been
reported (Gratton et al., 2003; Estrada and Dunn, 2010) and are
supported by most of FLIM manufacturers.
In both methods the lifetime in every pixel is calculated using
curve ﬁtting algorithms, with the least squares criterion being the
most common. This method relies on calculation of the lifetime of
one or several components in the tissue simultaneously. Comple-
mentary approaches in dealing with the complexity of multi-
exponential images that are often seen in autoﬂuorescence FLIM
(see below) include stretched exponential (Lee et al., 2001), global
ﬁtting algorithms (Pelet et al., 2004), the Laguerre deconvolution
method (Jo et al., 2006), and the phasor analysis method (Redford
and Clegg, 2005; Digman et al., 2008).
2.3. Natural ﬂuorophores of the retina using ex vivo FLIM
The retina and nearby tissue is rich with endogenous ﬂuo-
rophores (Fig. 2) that absorb and emit in the 250 nm to nearly
700 nm range (Table 1). However, because of UV ﬁltering properties
of the cornea and lens, wavelengths below do not enter or exit the
eye, and as such cannot be measured in vivo. This section provides
information about lifetime characteristics of ﬂuorophores found in
the retina ex vivo by using FLIM. Autoﬂuorescence FLIM is an
attractive modality because it does not require administration of a
ﬂuorescent dye. However, the low signal of autoﬂuorescence, and
the complex nature of autoﬂuorescence spectrally overlappingwith
several ﬂuorophores, each with a variable lifetime, makes inter-
pretation of the images difﬁcult. Yet, the complicated landscape of
autoﬂuorescence carries substantial information regarding organ
pathology and provides an excellent opportunity for FLIM to deci-
pher the available data.
Retinal ﬂuorophores include aromatic amino acids that form
proteins and enzymes, redox-active chromophores which regulate
cell metabolism, structural proteins responsible for the shape and
ﬂexibility of the retina, and some ﬂuorescent pigments which are
markers of many age-related pathologies. A brief overview of
ﬂuorescent properties of retinal ﬂuorophores is given below.
2.3.1. Amino acids
Three amino acids, phenylalanine, tyrosine, and tryptophan are
ﬂuorescent (Supplementary Fig. 1). Of these amino acids, trypto-
phan is the only one useful for FLIM because of its broad emission
tail that goes beyond the 350 nm range where conventional FLIM
can be utilized. The ﬂuorescence of other ﬂuorophores occurs in the
deep UV region that cannot be detected by typical glass-based
microscopes. Phenylalanine and tyrosine suffer from low quan-
tum yield and poor molar absorptivity (Chen, 1967; Barrett and
Elmore, 1998) with weak emission at 350 nm. Tryptophan, with
its moderate molar absorptivity (5500 M1 cm1) (Barrett and
Elmore, 1998) and decent quantum yield (F ¼ 0.13) (Chen, 1967),
Fig. 2. Source of autoﬂuorescence in retina and surrounding tissue (with permission
from Han et al. 2007).
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strong exogenous ﬂuorophores in that range.
2.3.2. NADH
A reduced form of nicotinamide adenine dinucleotide (NADH)
and its phosphate derivative (NADPH) are the major endogenous
ﬂuorophores responsible for autoﬂuorescence in cells when excited
above 400 nm. NAD(P)H has an absorption maximum at 350 nm
and emits at 450 nm (Kierdaszuk et al., 1996). The oxidized form
NAD þ absorbs at a much shorter wavelength (~ 260 nm) and does
not ﬂuoresce. Protein bound NAD(P)H exhibits a relatively long
ﬂuorescence lifetime of 2.3e3.0 ns and a short lifetime ~ 0.3e0.4 ns
in the free form (Lakowicz et al., 1992; Blinova et al., 2005). This
decrease is due to facilitated rotation around the bond between the
pyridine and amide in the excited state. The difference in lifetime
between the free and protein bound forms is the basis of almost all
ﬂuorescence lifetime imaging techniques aimed at NADH (Wakita
et al., 1995; Schneckenburger et al., 2004) which is where bi-
exponential FLIM maps of cellular metabolism are typically
generated (Niesner et al., 2004).
2.3.3. Flavin
Flavin adenine dinucleotide (FAD) is a redox cofactor with
strong although oxidation dependent ﬂuorescent properties. As
with NAD(P)H, ﬂavin exists in several redox conﬁgurations (Kao
et al., 2008). Only the fully oxidized FAD form is ﬂuorescent. This
fully oxidized form emits at a longer wavelength than NAD(P)H and
has only a small overlap, allowing for selection of imaging condi-
tions speciﬁcally for FAD without spectral contamination from
NAD(P)H. The non-bound form of FAD has the longest lifetime ofTable 1
Endogenous ﬂuorophores responsible for autoﬂuorescence in the retina and nearby tissu
Fluorophore Excitation, nm Emission, nm
phenylalanine 258 (max) 240-270 280 (max)
tyrosine 275 (max) 250-290 300 (max)
tryptophan 280 (max) 250-310 350 (max)
NAD(P)H free 300e380 450e500
NAD(P)H protein 300e380 450e500
FAD free 420e500 520e570
FAD protein bound 420e500 weak in 520e570
retinal (Shiff base) 350 600e650
hemoglobin 400e600 non-ﬂuorescent
melanin 300e800 broad in NIR
collagen 280e350 370e440
elastin 300e370 420e460
lutein 440e540 550
zeaxanthin 440e540 550
lipofuscin 340e500 540,430-460
Abbreviations: nicotinamide adenine dinucleotide (NADH); nicotinamide adenine dinuc
ﬂuorescence (NIR); nanometer (nm); nanoseconds (ns).2.3e2.9 ns, while protein binding leads to a signiﬁcant decrease of
the lifetime to <0.1 ns (Nakashima et al., 1980; Maskevich et al.,
1997), apparently due to the presence of adjacent aromatic resi-
dues in the protein binding pocket (Yang et al., 2003; Kao et al.,
2008).
2.3.4. Melanin
Melanin constitutes a diverse group of pigments produced by
melanocytes and found in the eyes to protect them from UV and
high-intensity visible light. Melanin is composed from a complex
mixture of largely unknown biopolymers derived from tyrosine
(Ito, 1986). With respect to the eye, important members of the
melanin family are eumelanin and pheomelanin (Supplementary
Fig. 1). Eumelanin is more common in brown-eyed people, while
pheomelanin is found in blue- and green-eyed population (Kolb,
2007). The emission decay of melanin is complex, as would be
expected from its featureless absorption spectra and the lifetime
ranges from picoseconds to almost 8 ns (Forest et al., 2000; Ehlers
et al., 2007).
Under the near-infrared illumination (i.e. 785 nm), melanin is a
relatively strong ﬂuorophore (Huang et al., 2006) and a major
source of near-infrared fundus autoﬂuorescence (NIR-AF) (Gibbs
et al., 2009). Under ultraviolet or short visible light, melanin
shows a relatively poor quantum yield with low emission. Because
of this optical behavior, melanin was considered to be non-
ﬂuorescent under UV-VIS light excitation. However, under the
oxidizing conditions, the oxidized form of melanin exhibits a
lipofuscin-like yellow ﬂuorescence with excitation max at
450e470 nm and emission at 540 nm (Gallas and Eisner, 1987;
Kayatz et al., 2001).
2.3.5. Lipofuscin
The visual cycle begins with the photoisomerization of retinal.
When the 11-cis-retinal chromophore, bound to the trans-
membrane portion of the photoreceptor cell opsin, absorbs a
photon, it isomerizes from the 11-cis state to the all-trans state. This
conformational change in the opsin leads to a cascade of signaling
reactions leading to an electrical response in the photoreceptor. The
recycling of all-trans-retinal to the 11-cis conformation includes
conversion of the all-trans-retinal to all-trans-retinol by all-trans-
retinol-dehydrogenase. Although most all-trans-retinal is recy-
cled, some all-trans-retinal, which is not bound to opsin, can enter a
nonenzymatic reaction with phosphatidylethanolamine (PE) to
create N-retinylidene-PE or alternatively, fusion with a second all-
trans-retinal to create a bisretinoid molecule A2-PE-H2. RPEe.
Lifetime, ns References
7.5 (McGuinness et al., 2006)
2.5 (Ashikawa et al., 1982)
2.0e6.0 (Guo et al., 2012; Guo et al., 2013)
0.3 (K€onig, 2008)
2.0e2.3 (K€onig, 2008)
2.91 (Koziol et al., 2006; K€onig, 2008)
<0.01 (Schweitzer et al., 2007b)
0.030e0.1 (Bachilo and Gillbro, 1999)
n/a e
0.65e1.6 (K€onig, 2008)
5.3 (Maarek et al., 2000; K€onig, 2008)
2.3 (Maarek et al., 2000; K€onig, 2008)
0.03e0.08 (Barker et al., 2011; Dysli et al. 2016e)
0.03e0.08 (Barker et al., 2011; Dysli et al. 2016e)
up to 2.2 (Sparrow et al., 2000; Schweitzer et al., 2007b)
leotide phosphate (NADPH); ﬂavin adenine dinucleotide (FAD); near-infrared auto-
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A2E, A2-PE-H2 and A2-PE and is predominantly found in an
intracellular organelle, the lysosome (Spaide, 2008). Lipofuscin is a
pale, yellow-brown pigment of varied molecular weight (Taubold
et al., 1975) mostly visible in skin as the so-called “age” or “liver”
spots. (Supplementary Fig. 1), with some minor cis-trans isomers
and phosphatidyl analogs. Lipofuscin is formed in the cytoplasm of
muscle and nerve cells and has been implicated in age-related
diseases of the retina, such as macular degeneration and Stargardt
disease (Sparrow and Boulton, 2005).
By selecting an appropriate set of excitation and emission con-
ditions, lipofuscin can be distinguished from other ﬂuorophores in
tissues. In the window of 440e470 nm excitation and 510e700 nm
emission, lipofuscin was found to be the brightest endogenous
ﬂuorophore (Schweitzer et al., 2007b). The decay of lipofuscin
in vivo is multiexponential due to a heterogeneous microenviron-
ment consisting of multiple ﬂuorophores with a variety of energy
transfers. Several studies have revealed at least two major com-
ponents with lifetimes of 390 ps and 2.2 ns. The short component
has been used to distinguish lipofuscin from other ﬂuorophores
present in the retina, such as bound NAD(P)H, melanin, and
collagen (Schweitzer et al., 2007b).2.3.6. Retinal
Retinal bound to rhodopsin (Supplementary Fig. 1) by itself is
only weakly ﬂuorescent with an extremely low quantum yield
(Alexiev and Farrens, 2014). The Schiff base of retinal, a model of the
chromophore, shows its absorption maximum at 360 nm and
emission at ca. 610 nm with a lifetime of 56 ps in ethanol (Bachilo
and Gillbro, 1999). Retinoid binding proteins have very weak and
ultrafast ﬂuorescence because of excited-state photochemical re-
actions. The most important one among them is the rapid cis-trans
isomerization that occurs in <1 ps (Doukas et al., 1984). The short
lifetime is unlikely to be distinguished from the instrument
response function on most of commercial FLIM systems.2.3.7. Lutein and zeaxanthin
Lutein and zeaxanthin are the predominant carotenoids found
in the retina and are mainly located in the macular center, leading
to the yellowish color of the fovea (Schalch, 1992; Widomska and
Subczynski, 2014). They play an important role as antioxidants to
prevent against oxidative stress (Bernstein et al., 2016). Due to the
absorbance maximum of lutein and zeaxanthin around 460 nm,
both compounds act as blue ﬁlters for UV light (Barker et al., 2011).
Both pigments show weak and broad emission at 550 nm max.
Fluorescence lifetime of lutein and zeaxanthin in solution excited at
473 nm is below 100 ps (see Table 1 and Section 4). However, in the
aggregated form, the lifetime of zeaxanthin has been reported to
reach 1.06 ns when measured at an emission of 680 nm (Gruszecki
et al., 1990).2.3.8. Collagen and elastin
Collagen is a slightly ﬂuorescent structural protein consisting of
a network of ﬁbrils. It can be observed in the retina, contributing to
retinal architecture and stability, as well as vitreoretinal adhesion
and stability of the vitreous gel (Sebag, 1992; Ponsioen et al., 2008).
Elastin is rare in the human retina. It is found in retinal arteries
(Chen and Weiland, 2014) as a regulator of contractility and blood
ﬂow in the retinal vascular system. Both, collagen and elastin, show
emission of up to 500 nm when excited with UV of up to 350 nm
(Zheng et al., 2008) or with two-photon excitation using red lasers
(Han et al., 2005).3. Technical principles of ﬂuorescence lifetime imaging
ophthalmoscopy
In the last four decades, imaging of intrinsic retinal ﬂuorophores
has mainly focused on intensity measurements. However, in the
last years efforts have beenmade to include ﬂuorescence lifetime as
an additional dimension leading to combined time- and intensity-
resolved autoﬂuorescence measurement. The ﬂuorescence lifetime
is a photophysical and echemical function and describes the
average time a molecule remains in its electronically excited state
after absorbing the energy of a photon and before returning to the
ground state by emitting a photon. This process follows an expo-
nential decay and the time scale is typically in the order of pico- to
nanoseconds. Equation (1) represents the sum of ﬂuorescence,
indicated as ﬂuorescence intensity (I), at time (t) with the respec-
tive ﬂuorescence lifetime (T) and amplitude (a), depending on the
number of decay components.
IðtÞ ¼ Ið0Þ*
Xn
i¼1
aie
 tti (1)
I: intensity
T: lifetime
n: number of components
a: weighting, amplitude
The ﬂuorescence lifetime is not only dependent on the molecule
itself, but also on its local environment. It is therefore a promising
parameter for metabolic processes in the retina.
The decay of the excited state of the ﬂuorophore is a statistical
process. Hence, to derive ﬂuorescence lifetimes, a number of decay
cycles must be measured. For every single ﬂuorophore, detection
time upon excitation is measured and sorted into different time
channels, which then form an exponential function.3.1. Pulsed ﬂuorescence excitation and decay histogram
Experimentally, each ﬂuorescent photon has to be precisely
registered according to its arrival time at the detector upon exci-
tation and corresponding position on the retina. Therefore, the FLIO
system consists of a pulsed laser source and a sensitive detector for
registration of every single photon. A confocal laser scanning
ophthalmoscope (cSLO) is the basis for image recording throughout
the acquisition process.
The resulting histogram of the ﬂuorescence decay can be ﬁtted
by an exponential function (see Fig. 3 A). For a single ﬂuorophore,
the decay function should theoretically be mono-exponential.
However, several factors inﬂuence the shape of the exponential
decay:
 Interaction of more than one ﬂuorophore specimen
 Time distribution of the excitation photon bunch
 Movement artifacts
Usually, more than one ﬂuorophore specimen is present.
Currently, the depth resolution does not allow to measure ﬂuo-
rescence in single retinal layers. Therefore, with the FLIO imaging
devices, ﬂuorescence lifetimes across the entire retinal depth are
measured. This results in ﬂuorescence lifetimes which are
composed from a variety of different ﬂuorophores or from the same
ﬂuorophores but with different local environments. Hence, the
resulting histogram of photon decay times is a mixture of the most
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Within the exponential decay of the ﬂuorophores (equation (2))
the instrument response function (IRF) is integrated which repre-
sents the temporal behavior of the detectors. During data analysis,
the inﬂuence of the instrument (IRF) has to be cancelled, so that
only the data resulting from the ﬂuorophores are analyzed.
I*ðtÞ ¼ IRF5IðtÞ (2)
The ﬂuorescence is not always decayed after one measurement
period of 12 ns. As a standard approach, repetitive measurement of
periods or cycles of 12 ns are performed and integrated over time.
This is especially important for long lifetimes, because photons
from a previous cycle can leak into the next cycle and inﬂuence the
calculation results.
The higher the order of the exponent, the more ﬂuorophores
might be distinguished. However, increasing exponents necessitate
higher numbers of photons to satisfy statistical requirements for
accurate exponential decay approximation. Therefore, a compro-
mise between precise ﬁtting and enough photons needs to be
found. For high spatial resolution, a low binning factor of 0 or 1 is
used, requesting accumulation of sufﬁcient photons per individual
pixel. A binning factor of 0 indicates that photons of one single pixel
location are considered for the exponential decay function. How-
ever, 1 means that the photons from the immediately neighboring
pixels are also included, increasing the number of photons by nine.
In cases of low amount of photons detected per pixel, the binning
factor needs to be increased accordingly, leading to a larger area
with the same ﬂuorescence lifetime and thereby a lower spatial
resolution. Depending on the type of disease, either higher spatial
resolution or a more precise curve ﬁt of the recorded lifetime data
can be chosen. In our hands, a binning of 1 and a bi-exponential
curve ﬁt seems to be appropriate in most diseases.3.2. Fluorescence lifetime imaging ophthalmoscope
The ﬂuorescence lifetime imaging ophthalmoscope is based on a
Heidelberg Retina Angiograph cSLO (HRA2, Heidelberg Engineer-
ing). Fig. 3B) and C)) shows schematical illustrations of the FLIO
setup. It is equipped with an infrared camera for active eye tracking
(TruTrack) to correct for eye movements and thereby to ensure
correct live registration of each arriving photonwithin a 256  256
pixel frame. The ﬂuorescence lifetime imaging ophthalmoscope has
been modiﬁed and synchronized with a picosecond pulsed illu-
mination excitation diode laser at 473 nm (Becker&Hickl). Auto-
ﬂuorescence excitation occurs with a confocal laser beam, raster
scanning the central 30 of the fundus with a frame rate of 9 Hz and
a laser repetition rate of 80 MHz. Two spectrally separated highly
sensitive single photon counting detectors (HPM-100-40, Beck-
er&Hickl) connected to two time-correlated single photon counting
cards (TCSPC, Becker&Hickl) are responsible for detection of every
single emitted ﬂuorophore. According to their wavelength, photons
are separately detected in two channels: a short spectral channel
(wavelength 498e560 nm, SSC) and a long spectral channel
(560e720 nm, LSC). The laser and the detectors are controlled by a
detector control module (Becker&Hickl). Over the entire scan
duration, repetitive measurement periods, each 12 ns apart, are
performed at each pixel of the scan. The detected photons are then
put into a histogram with time channels of 12.5 ps.
All parts of the current FLIO device are integrated into the
Heidelberg engineering cSLO architecture and fulﬁll laser safety
class 1 considerations which comply with ANSI Z136.1e2007 (ANSI,
2007) and International Electrotechnical Commission (IEC, 2014).
The instrument is controlled with a modiﬁed version of the Hei-
delberg Eye Explorer (HEYEX) software (Heidelberg Engineering)and the ﬁnal lifetime calculation is done with an integrated version
of SPCImage (Becker&Hickl).3.3. Image acquisition and analysis
Standard FLIO image acquisition is usually performed with
maximally dilated pupils to reduce inﬂuence of lens auto-
ﬂuorescence lifetimes, as in mydriasis the time-correlated photon
counts from retinal ﬂuorophores are higher. Eyes with clinically
signiﬁcant lens opacities were excluded for the studies included in
this review. As in autoﬂuorescence intensity imaging, image quality
is decreased in cases of signiﬁcant cataract, and longer auto-
ﬂuoescence lifetimes are measured. Within the macular center, we
recommend to acquire a minimum of 1000 photons per pixel in
both channels, resulting in a total scan duration of about 90 s. As the
autoﬂuorescence lifetimes are generally insensitive to moderate
levels of photobleaching (Ishikawa-Ankerhold et al., 2012), this
effect can be neglected in FLIO. Additionally, the ﬂuorescence life-
times are averaged over the entire scan duration, and thereby
possible time dependent effects can be excluded. Currently, no
photo-oxidative changes can be measured in vivo (Teussink et al.,
2017).
SPCImage software from Becker&Hickl can be used for analysis
of the recorded ﬂuorescence lifetime data. In both wavelength
channels and for each location, a photon distribution histogram is
built over the time span of 12.5 ns. To increase the numbers of
photons for the exponential decay curve ﬁt, a binning factor of one
can be used, averaging the photons of an individual pixel point with
the directly adjacent pixels.
The acquired data is ﬁtted by an exponential decay curve (Fig. 4
A þ B). Comparison of bi-versus three-exponential decay functions
revealed insigniﬁcant differences between these two models for
the mean ﬂuorescence lifetime within a study population of 31
healthy subjects (Correlation of 0.996 in both spectral channels, see
Supplementary Fig. 2). Consistency of analysis within one study is
important. The goodness of ﬁt of the exponential decay function is
indicated by the x2 value, whereby low parameters indicate an
appropriate ﬂuorescence lifetime ﬁt. The x2 value ranged between
1.1 and 1.3. Bi- versus three-exponential analysis did not inﬂuence
the x2 value substantially if the ﬁt was appropriate.
The determined bi-exponential decay function resulted in the
following individual lifetime components within the SSC and the
LSC: a short (T1) and a long (T2) decay time with their corre-
sponding relative amplitudes (¼ relative intensity) a1 and a2
(Fig. 5). Within the ocular fundus, T1 is much shorter than T2 and
the amplitude a1 is much higher than a2. A main outcome
parameter, representing all abovementioned ﬂuorescence lifetime
components, is the mean ﬂuorescence lifetime tau mean (Tm). It
represents the amplitude weighted mean ﬂuorescence decay time
per pixel and wavelength channel. Tm is calculated from the indi-
vidual four lifetime components T1, T2, a1, and a2:
Tm ¼ a1*T1 þ a2*T2
a1 þ a2 (3)
Two dimensional distribution histograms (2D) can be used for
visualization of individual lifetime components such as the short
and the long decay parameters T1 and T2. Thereby, lifetime clouds
of speciﬁc retinal locations can be identiﬁed. Fig. 4 C) shows the 2D
lifetime distribution histogram of a healthy subject.3.4. Image analysis software
For clinical image analysis, FLIO data can be analyzed using the
custom made ‘FLIO reader’ (ARTORG Center for Biomedical
Fig. 3. A) Fluorescence excitation and emission pathway and ﬂuorescence decay histogram. The excitation laser raster scans the retina in multiple periods (1,2,3,…,n) and detects
and integrates every single emitted ﬂuorophore and builds up a distribution histogram over time. B) Schematic illustration of the FLIO system. C) Technical setup of the FLIO system.
Beam splitter (BS), ﬁxation target (F), scanning mirror (SM), mirror (M), detector (D, short (SSC, 498e560 nm) and long (LSC, 560e720 nm) spectral channel), laser (L, 473 nm),
TCSPC module (T), detector control module (DC).
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FLIMX software (M. Klemm, Ilmenau, Germany) (Klemm et al.,
2015). They allow continuous overlay of the ﬂuorescenceintensity image and the color coded image of single lifetime
components (Tm, T1, T2, a1, a2, photon count, chi-square value,
Fig. 5). A standard Early Treatment Diabetic Retinopathy Study
Fig. 4. FLIO imaging in the healthy retina. A) Representative fundus autoﬂuorescence intensity (FAF) and mean ﬂuorescence lifetime image (FLIO; long spectral channel (LSC)
560e720 nm; color range Tm: 200e1000 ps) of the right eye of a 35 years old healthy subject. For comparability, the same settings (LSC, consistent color range if not further
speciﬁed) is used for further illustration in retinal pathologies. B) Calculated ﬂuorescence decay curves over the time interval of 12 ns for individual pixel locations (1e4) marked in
A). C) 2D histogram showing the distribution of ﬂuorescence lifetime clouds for speciﬁc retinal areas when plotting the short decay component T1 (x-axis) versus the long decay
component T2 (y-axis) according to equation (3). Note the different time scales used for the axis.
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3 mm for the inner ring (IR) and 6 mm for the outer ring (OR) can
be used to analyze areas of interest (Dysli et al., 2014b). The grid is
adjustable in position and if needed also in size. It enables aver-
aging of single lifetime components and provides corresponding
standard deviation values for all of the nine subﬁelds of the grid.
For speciﬁc analysis, a small region of interest (circle diameter of
0.2 mm) can be used.4. Fluorescence lifetimes of retinal ﬂuorophores ex vivo
In order to illustrate the lifetime contribution of possible indi-
vidual retinal ﬂuorophores, single compounds can be measured
and analyzed individually using FLIO. As these measurements are
usually performed in vitro and independent of the ocular system
consisting of cornea, lens, vitreous body, and all retinal layers, the
acquired data might not be directly transferable to in vivo
Fig. 5. Illustration of individual lifetime components according to equation 3 (LSC). A)
Autoﬂuorescence intensity image with indicated standard ETDRS grid which was used
for quantitative analysis of lifetime values within the individual rings and subﬁelds (C:
center subﬁeld, d ¼ 1 mm; IR: inner ring, d ¼ 3 mm; OR: outer ring, d ¼ 6 mm). B)
mean ﬂuorescence lifetime with adjusted color range with minimal to maximal ﬂuo-
rescence lifetime (Tm: 200e350 ps). C þ D) Amplitude and lifetime of the short decay
component. Note that the amplitude a1 contributes to 92e98% with the very short
decay component T1 of 150e200 ps. E þ F) Amplitude and lifetime of the long decay
component. Note that the amplitude a2 contributes only to 2e8% with the extremely
long decay component T2 of 1500e2000 ps. G) The distribution of the photon count
ranged between less than 1500 photons in the macular center, the optic nerve head
and the retinal vessels and 5800 photons in the area of the peripheral retina. H) The
chi2 value indicates the goodness of the exponential ﬁt with main values between 1,0
and 1,5.
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studies.
The shortest retinal autoﬂuorescence lifetimes are observed
within the macular center and are assumed to be caused bymacular pigment (Sauer et al., 2015; Sauer et al., 2016). Themacular
pigment mainly consists of the retinal carotenoids lutein and
zeaxanthin (Wustemeyer et al., 2003; Neuringer et al., 2004;
Johnson et al., 2005; Leung et al., 2005; Barker et al., 2011; Lima
et al., 2016). Its absorption spectrum lays between 400 and
540 nm with a peak at 460 nm. Our measurements using the FLIO
system with 473 nm excitation wavelength revealed mean auto-
ﬂuorescence lifetimes for lutein and zeaxanthin between 41 and 84
ps in the short spectral channel (498e560 nm) and 31e58 ps in the
long spectral channel (560e720 nm; (Dysli et al., 2016e). This
supports the hypothesis that carotenoids, even though they are not
detectable in fundus autoﬂuorescence intensity measurements,
might contribute to short retinal ﬂuorescence lifetimes.
Other ﬂuorophores residing in retina are known to originate as
by-products of the visual cycle. FLIO measurements of the visual
cycle compound retinal revealed very short decay times with
values around 82e85 ps in the short, and 32e47 ps in the long
spectral channel. All-trans-retinal is an intermediate substrate
within the visual cycle before reduction to all-trans-retinol or e in
case of accumulation of all-trans-retinal e formation of all-trans-
retinal dimers and subsequent conjugation with phosphatidyleth-
anolamine (Fishkin et al., 2004; Fishkin et al., 2005).
On the other hand, ﬂuorescence lifetimes of retinol were be-
tween 330 and 566 ps in both detection channels. Given that the
excitation peak of retinol is below 400 nm and therefore not
reaching the retina due to absorption by the lens, it is unlikely that
retinol ﬂuorescence lifetimes contribute signiﬁcantly to retinal
ﬂuorescence lifetimes in vivo. Retinal is the aldehyde form of
vitamin A that is generated from vitamin A (retinol) by oxidation.
Although all-trans-retinal has not been shown to exhibit ﬂuores-
cence at 488 nm excitation, all-trans-retinal derivates such as the
all-trans-retinal dimer-phosphatidylethanolamine formed in the
outer photoreceptor segments display ﬂuorescence at this excita-
tion wavelength. Deposition of shed but not phagocytized outer
segments containing retinaldehyde adducts such as alletrans-
retinal dimer in the subretinal space due to separation of the outer
segments from the RPE may contribute to short lifetimes such as
seen in newly arisen deposits in Stargardt disease and active lesions
in central serous chorioretinopathy (Dysli et al., 2016b,c,d; Dysli
et al., 2017). In Stargardt disease, a defect in the ABCA4 trans-
membrane transport protein, which is involved in the transport of
N-retinylidene-PE across the outer segment disks of the photore-
ceptors, leads to accumulation of all-trans-retinal derivatives
within the outer segment before phagocytosis (Spaide, 2008).
With increasing age and in retinal dystrophies such as Stargardt
disease, these compounds are deposited and accumulate in the RPE
as lipofuscin. Melanin might be another possible source of retinal
autoﬂuorescence lifetimes (Weiter et al., 1986). Melanin has a
strong, broadband absorption with a peak around 380 nm. How-
ever, the emission is quite low and peaks at around 450 nm (Gallas
and Eisner, 1987). On conventional fundus autoﬂuorescence in-
tensity images, melanin absorbs the short-wavelength excitation
beam, decreasing the overall autoﬂuorescence signal (Yung et al.,
2016). FLIO measurement of pure melanin featured long values
with decay times between 648 and 1600 ps (Dysli et al., 2016e).
5. Fluorescence lifetime imaging ophthalmoscopy
5.1. FLIO in healthy retina
We have reported on the basic features of autoﬂuorescence
lifetime imaging of the human retina in a study population of 31
healthy subjects with an age range between 22 and 61 years (mean
age 35± 11 years) (Dysli et al., 2014b). In both spectral channels, the
shortest ﬂuorescence lifetimes were measured within the foveal
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Fig. 6. Quantitative analysis of retinal autoﬂuorescence lifetime values in healthy
subjects. Correlation of mean ﬂuorescence lifetimes of the inner ring with age in both
spectral channels (SSC: r2 ¼ 0.617, p < 0.001; LSC: r2 ¼ 0.647, p < 0.001).
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spectral channel. In this area, the ﬂuorescence intensity was
decreased due to the presence of macular pigment. This is in
agreement with other studies showing congruence of macular
pigment optical density measurements with short ﬂuorescence
lifetimes in an independent population of healthy subjects (Sauer
et al., 2015; Sauer et al., 2016). Towards the retinal periphery,
longer lifetimes were measured. These areas correlate with the
topographic distribution of the bisretinoids of retinal lipofuscin
(Delori et al., 1995).
The longest mean ﬂuorescence lifetimes can be detected within
the area of retinal vessels and the optic nerve head, possibly due to
a higher content of connective tissue components such as collagen
and elastin. Characteristic ﬂuorescence decay curves for speciﬁc
locations on the posterior pole of the eye are shown in Fig. 4A) and
B). Quantitative autoﬂuorescence intensity, which is mainly based
on lipofuscin, is highest 10e15 around the foveal center with
slightly decreasing values towards the periphery (Greenberg et al.,
2013).
When analyzing the individual ﬂuorescence decay components
T1 and T2, a typical lifetime distribution can be shown in a 2D
histogram (Fig. 4 C). Thereby, retinal landmarks such as the fovea,
the retina, retinal vessels and the optic nerve head can be
differentiated.
Repeated measurements using FLIO show a high reproducibility
and a low coefﬁcient of variation between measurements of fellow
eyes and between repeated measurements within one subject with
same pupil dilation size (Dysli et al., 2014b). Furthermore, the in-
ﬂuence of pupil size on ﬂuorescence lifetimes was investigated. In
non-dilated eyes a shift towards longer ﬂuorescence lifetimes was
observed (Dysli et al., 2014b). This may derive from a lower efﬁcacy
of detection of retinal ﬂuorophores in non-dilated eyes and possibly
stronger ﬂuorescence lifetime effects of the crystalline lens. There
were no differences found in ﬂuorescence lifetime distribution
between female and male subjects.
With age, retinal ﬂuorescence lifetimes become longer in both
spectral channels (see Fig. 6). This is probably the result from
progressive accumulation of retinal metabolic by-products such as
lipofuscin, and change in the composition of the contributing ﬂu-
orophores, which ﬁnally results in a shift towards longer lifetimes.
Additionally, progressive subclinical media opacities might
contribute to prolonged mean ﬂuorescence lifetimes with
advancing age. In keeping with this, quantitative autoﬂuorescence
intensity was shown to increase with age between 20 and 70 years
(Greenberg et al., 2013).
5.2. FLIO and macular pigment
Fluorescence lifetime imaging of healthy eyes shows typical
patterns, whereby shortest mean ﬂuorescence lifetimes (Tm) are
found in the macular center. Schweitzer et al., who ﬁrst described
these local differences in 2004, proposed that the short auto-
ﬂuorescence lifetimes originate from within the retinal pigment
epithelium (Schweitzer et al., 2004) (Schweitzer et al., 2007b). This
assumption was based on two-photon excited autoﬂuorescence
imaging of ex vivo porcine retinal cells, conﬁrming short ﬂuores-
cence lifetimes within RPE cells (Peters, 2011). Because of the
inherent thinning of the neuroretina at the fovea and in consider-
ation of these ex vivo studies, it was initially thought that the short
ﬂuorescence lifetimes observed in the human macula were a
consequence of short lifetimes derived from the melanin contained
in the RPE layer. Because macular carotenoids contained in the
macular pigment are strong blue light absorbers, it was originally
assumed that they do not inﬂuence ﬂuorescence lifetimes. How-
ever, with the work of Delori it was shown that macular pigmentdensity inﬂuences lipofuscin ﬂuorescence and therefore can be
imaged indirectly using fundus autoﬂuorescence intensity mea-
surement (Delori, 2004). Studies on patients with macular holes
gave further evidence on the impact of macular pigment on the
short ﬂuorescence lifetimes (Sauer et al., 2016). It is now assumed
that the short ﬂuorescence lifetimes in themacular region originate
from the macular pigment.
Macular pigment, mainly consisting of the carotenoids lutein,
zeaxanthin, andmeso-zeaxanthin, is located in the plexiform layers
and photoreceptor axons (Henle's layer) in the macula lutea
(Snodderly et al., 1984; Landrum and Bone, 2001; Krinsky, 2002;
Trieschmann et al., 2008). It absorbs the short-wavelength excita-
tion light, causing a hypoﬂuorescent central macula in auto-
ﬂuorescence images (Delori et al., 2001). Different distribution
patterns of macular pigment in fundus autoﬂuorescence have been
described (Ermakov et al., 2005; Sharifzadeh et al., 2006). In 2015, a
strong correlation of short macular Tm with macular pigment op-
tical density measurements was found, providing indirect evidence
that the very short ﬂuorescence lifetimes in the macula derive from
the inﬂuence of macular pigment (Sauer et al., 2015). The ﬂuores-
cence lifetime of xanthophylls in vitro is very short, with approxi-
mately 200e250 fs (Kandori et al., 1994; Sharifzadeh et al., 2006).
The time resolution of FLIO is limited to approximately 30 ps.
Therefore, the autoﬂuorescence of macular carotenoids in vivo
shows apparently longer lifetimes as compared to the in vitro life-
times. Accordingly, the shortest ﬂuorescence lifetimes detected
with FLIO are found within the fovea and show ﬂuorescence life-
times of approximately 30e50 ps (Tm in the SSC) (Sauer et al.,
2015). The macular region, presumably containing a large fraction
of carotenoid ﬂuorescence, also contains a fraction of ﬂuorophores
with longer ﬂuorescence lifetimes, such as lipofuscin or melanin. As
such, ﬂuorescence lifetimes in the macula are likely to result from a
superposition of many ﬂuorophores including lipofuscin and
macular pigment. One may argue about the impact of ﬂuorescence
of macular pigment in that context, as lipofuscin is reported to
show greater ﬂuorescence efﬁciency (102) than macular pigment
(104) (Lamb et al., 2001; Bhosale et al., 2009a).
In general, known lipofuscin components in vitro showlonger Tm
(1352 ps) than the shortest mean ﬂuorescence lifetime that is
detected with FLIO in the macular region in vivo (Schweitzer et al.,
2004) (Schweitzer et al., 2007b). Short autoﬂuorescence lifetimes
are only reported for the component A2E (16 and 189 ps); yet, a
declinewithin thedistributionofA2Eat themacular regionhasbeen
found (Lamb et al., 2001; Schweitzer et al., 2004; Bhosale et al.,
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A2E can explain the short macular Tm (Sauer et al., 2015).
However, the ﬂuorescence of lipofuscin is strongly reduced by
macular pigment, which is found within approximately 1 mm (4)
from the central fovea and is located anterior to the RPE. Macular
pigment has an absorption spectrum of 400e540 nm, peaking at
approximately 460 nm (Bone et al., 1992). Macular pigment is not
only acting as an excitation and emission ﬁlter on the lipofuscin
autoﬂuorescence, it is also a major contributor to macular auto-
ﬂuorescence lifetimes, and thereby causing the shortest lifetimes
observed in the human retina. The impact of this has to be
considered as ﬂuorescence lifetimes are meant to be largely inde-
pendent of the ﬂuorophore's concentration. However, because
ﬂuorescence lifetimes in the retina are an amalgamation of various
ﬂuorophores, the concentration of a given ﬂuorophore in the retina
in a given location is likely to inﬂuence the mean ﬂuorescence
lifetimes. The decay curve of the mean ﬂuorescence lifetime will be
dominated by the most prominent ﬂuorescence lifetime at this
location. Fluorescence lifetimes can be detected even in areas
where the ﬂuorescence intensity is very weak.
In keeping with this assumption, it was found that macular Tm
shows a strong correlation with the amount of macular pigment,
independent of the subject's age or the retinal thickness. Xantho-
phylls in vitro show a ﬂuorescence emission of approximately
500e580 nm and a peak at 520e540 nm (Sharifzadeh et al., 2006).
Due to the peak emissionwavelength, the SSC is more inﬂuenced by
macular pigment ﬂuorescence than the LSC, which is reﬂected in a
stronger correlation for the SSC (Snyder et al., 1985; Cosgrove et al.,
1990; Decoster et al., 1992; Andersson and Gillbro, 1995; Sauer
et al., 2015).
The macular pigment distribution varies between individuals
independent of the sex. The fractional contribution of macular
pigment is reﬂected in the ﬂuorescence lifetimes; a higher frac-
tional contribution of the xanthophylls leads to a shorter Tm. As
shown in Fig. 7, the different distribution patterns of macular
pigment are reﬂected in ﬂuorescence lifetime images and can be
distinguished (A: broad shaped, B: cone shaped).
5.3. FLIO and macular holes
Full-thickness idiopathic macular holes are full-layer defects of
the retina located at the fovea. Here, the neuronal retinal layers
containing macular pigment are disrupted and dislocated to the
side of the defect. Solely the RPE is left inside the macular hole. The
ﬂuorescence lifetime patterns in eyes with macular holes differ
from the pattern found in healthy eyes (Sauer et al., 2016). The
lifetimes inside the defects were signiﬁcantly longer compared to
intact macular regions. Short ﬂuorescence lifetimes were found
adjacent to the macular holes, often in a ring-shaped manner. They
appeared to be dislocated in the same manner as the retinal layers
were dislocated to areas besides the defect (Sauer et al., 2016). Fig. 8
A) shows an example of a full thickness macular hole.
Additionally, macular holes with opercula were described
(Sauer et al., 2016). An operculum is a small piece of detached retina
above the defect that often contains macular pigment (Gass and
Van Newkirk, 1992; Ezra et al., 1997). The ﬂuorescence lifetimes
of the opercula were comparable to those adjacent to the defect as
well as the healthy fovea. The same ﬂuorophores must be likewise
present, always co-located with macular pigment. This supports
the conclusion that macular pigment is responsible for the short
mean ﬂuorescence lifetimes (Sauer et al., 2016).
Follow-up examinations after successful macular hole closure
with surgery showed a foveal region with ﬂuorescence lifetimes
very similar to the fovea in healthy eyes. Here, the neuronal retinal
layers were relocated towards their original position (Sauer et al.,2016). FLIO does not show the layers that are located back to-
wards the fovea like OCT, but it shows if the cells containing mac-
ular pigment, that originally were at the fovea, were relocated. This
may be used to assess the outcome of the surgery. Fig. 8 B) shows an
example after successful macular hole surgery with a re-location of
short macular Tm. Visual acuity was shown to correlate signiﬁ-
cantly with Tm of the fovea one month after surgery.
In general, the distributions of macular pigment and short
ﬂuorescence lifetimes were congruent. It was observed that short
ﬂuorescence lifetimes are dis- and relocated in the same manner as
macular pigment is dis- and relocated in the foveal region (Sauer
et al., 2016). The short mean macular ﬂuorescence lifetimes can
be assigned to the macular pigment, and FLIO is indirectly able to
detect the distribution of macular pigment.
5.4. FLIO in retinal artery occlusion
Retinal artery occlusion (RAO) is characterized by sudden pain-
less loss of vision. Twomain forms can be distinguished: central and
branch retinal arteryocclusion (CRAOandBRAO). CRAO is associated
with a severe permanent vision loss (Hayreh and Zimmerman,
2005). The resulting oxygen undersupply of the retina leads to a
swelling of the inner retinal layers in affected areas in the acute
disease stage (Varmaet al., 2013). Fundoscopically., this presents as a
‘cherry red spot’ within themacular center due to an absence of the
swellingwithin the fovea andvisibility of the choroid. Over time, the
swelling reduces and an atrophy of the inner retinal layers can be
observed inOCT. Retinal arteryocclusion represents amodel disease
of acute retinal ischemia and therefore acute metabolic alterations.
In a recent study, FLIOwas used tomonitor retinal changes in retinal
artery occlusion (Dysli et al., 2015).
In this studyof 24patientswith central (meanage76±4years) or
branch (mean age 61 ± 7 years) retinal artery occlusion, patients
were imagedwith FLIO in the acute stage early after reported loss of
vision (<3 days) (Dysli et al., 2015). At this stage, retinal ﬂuorescence
lifetimes were signiﬁcantly prolonged in areas of RAO (Fig. 9).
Hypoxia is therefore thought to lead to decreased contribution of
ﬂuorophoreswith short autoﬂuorescence lifetimes and/or increased
inﬂuences of long ﬂuorescence lifetimes (Dysli et al., 2015).
Ischemia induces multiple changes of the cellular andmolecular
environment within the retina. These include formation of reactive
oxygen species (ROS), decrease in pH value, and changes in enzy-
matic activation, cytokine synthesis, gene activation and ionic
concentration (Bonne et al., 1998; Kuriyama et al., 2001; Siskova
and Wilhelm, 2001; Xu et al., 2004). Due to hypoxia, the ratio for
the oxidative phosphorylation of adenosine diphosphate (ADP) to
adenosine triphosphate (ATP) is changed as well. Thereby, the two
redox pairs NADþ/NADH (oxidized and reduced nicotinamide
adenine dinucleotide) and FAD/FADH2 (oxidized and reduced ﬂavin
adenine dinucleotide) might inﬂuence the measured ﬂuorescence
lifetimes. Whereas NADþ and FADH2 are non-ﬂuorescent, the
reduced NADH and the oxidized FAD show speciﬁc ﬂuorescence
properties depending on the excitation wavelength and their
protein-binding state (Lakowicz et al., 1992). As NADH shows very
short-wavelength excitation and emission spectra which will be
blocked by the lens and cornea, most likely it cannot be detected
using the present conditions in FLIO. However, FAD with an exci-
tation maximum at 450 nm and emission at 528 nm lies within the
detection range of FLIO (Heikal, 2010). Protein-bound FAD is
thought to contribute to very short ﬂuorescence lifetimes, and
therefore a shift towards reduced FADH2 and/or reduced protein-
binding of FAD due to hypoxia would lead to decreased contribu-
tion of short ﬂuorescence lifetimes and thereby longer ﬂuorescence
lifetimes in ischemic conditions. Additionally, fundus auto-
ﬂuorescence intensity measurements in RAO showed decreased
Fig. 7. Autoﬂuorescence lifetimes and macular pigment (MP). FLIO images (en face and 3D view; SSC) and 3D view of macular pigment optical density measurement in two in-
dividuals. A: broad shaped MP distribution. B: cone shaped MP distribution. Short ﬂuorescence lifetimes suit well to the distribution of macular pigment.
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swelling of the inner retinal layers (Mathew et al., 2010). This
phenomenon may also partly contribute to the measured pro-
longed ﬂuorescence lifetimes.
Over time, affected retinal areas developed atrophy of the
inner retinal layers. In this post-acute disease stage (>30 days),
ﬂuorescence lifetimes in the affected areas were comparable to
the unaffected fellow eyes (Dysli et al., 2015). Therefore, the
remaining thinned inner retinal layers contribute to the
measured mean autoﬂuorescence lifetimes in the same way asnormal inner retinal layers in healthy retinae.
5.5. FLIO in age-related macular degeneration
Age-related macular degeneration (AMD) is one of the leading
causes of vision loss in patients over 50 years in developed coun-
tries. AMD is classiﬁed in an early disease stage with presence of
retinal drusen and thickening of the Bruch membrane, and late
AMD. There are two forms of late AMD: neovascular AMD with
accumulation of intra- or subretinal ﬂuid, and dry AMD with
Fig. 8. Autoﬂuorescence lifetimes in macular holes. Fluorescence lifetime image of a patient with a full thickness macular hole before (A) and three months after surgery and
successful closure of the macular hole (B).
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2016).5.5.1. Drusen and reticular pseudodrusen
Drusen is a general term for focal deposits of extracellular debris
located between the basal lamina of the RPE and the inner layer of
Bruch membrane. It includes soft drusen of various sizes (small,
medium, large), hard drusen, cuticular drusen, crystalline drusen
and reticular pseudodrusen. Drusen and drusenoid deposits can be
related to normal aging process; however, they are also the main
sign of early AMD (Khan et al., 2016).
FLIO measurement in patients with AMD showed that the mean
autoﬂuorescence lifetimes of the retina in AMD was longer
compared to age matched healthy control eyes. (Dysli et al., 2016e)
This might be a sign of early accumulation of bisretinoids in the
RPE. In early stages, membranous debris from atrophic photore-
ceptor outer segments may not yet appear as visible in conven-
tional imaging techniques (Khan et al., 2016) When analyzing
speciﬁcally ﬂuorescence lifetime values of soft drusen and reticularpseudodrusen as the twomain forms of drusenoid deposits, a broad
range of ﬂuorescence lifetimes was detected. However, ﬂuores-
cence lifetimes of drusen and reticular pseudodrusen did not differ
signiﬁcantly from the surrounding retina. In ﬂuorescence intensity
images, soft drusen typically appear hyper-ﬂuorescent, especially at
the edges of the deposits. In contrast, reticular pseudodrusen do
not show hyper- but rather hypo-ﬂuorescence and are particularly
visible in infrared images. Their subretinal location is likely to block
the autoﬂuorescence from the underlying RPE (Khan et al., 2016)
and might therefore attenuate the contribution of relatively short
ﬂuorescence lifetimes deriving from the RPE, resulting in a general
shift towards longer lifetime values.
Hyper-ﬂuorescent areas with short retinal lifetimes were colo-
calized with hyper-dense deposits in the areas of degenerating
photoreceptor cells, especially the outer photoreceptor segments as
identiﬁed by OCT (Fig. 10 A) (Sparrow et al., 2015). These deposits
might contain high concentrations of visual cycle by-products such
as retinaldehyde adducts with short ﬂuorescence lifetimes similar
to what we have observed in early ﬂecks in patients with Stargardt
Fig. 9. Autoﬂuorescence lifetimes in inferior retinal artery occlusion: acute disease
stage.
Fundus autoﬂuorescence intensity (FAF), ﬂuorescence lifetime (FLIO, LSC), OCT of the
indicated green line in FAF image.
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with pigment epithelial bulging, which appear hyper-ﬂuorescent in
ﬂuorescence intensity measurement, were not directly visible in
FLIO measurement. On the other hand, areas of clearly prolonged
autoﬂuorescence lifetimes were co-localized with intraretinal de-
posits at the level of the photoreceptors. In these cases, the RPE-
photoreceptor band seemed to be highly altered and as such,
these lesions might reﬂect connective tissue remodeling rather
than photoreceptor activity.5.5.2. Geographic atrophy
The hallmark of dry late AMD is geographic atrophy which leads
to irreversible central vision loss due to progressive degeneration of
the RPE, the choriocapillary layer, and the outer retina (Bowes
Rickman, Farsiu et al., 2013; Holz et al., 2014; Yung et al., 2016).
RPE atrophy and consequent loss of intrinsic ﬂuorophores results in
an area with a low to extinguished fundus autoﬂuorescence in-
tensity signal with sharply demarcated borders. Geographic atro-
phy lesions including the fovea are more difﬁcult to identify in
autoﬂuorescence intensity measurement due to low baseline con-
centration of lipofuscin and absorption interference by macular
pigment (Yung et al., 2016). Typically, lesions of geographic atrophy
are surrounded by hyper-ﬂuorescence, which represents areas of
photoreceptor and RPE dysfunction and deposits. Using auto-
ﬂuorescence intensity measurement, different forms of geographic
atrophy are described in literature with speciﬁc morphological
characteristics and respective prognostic values. According to the
distribution of hyper-ﬂuorescence around the lesion of atrophy, the
fundus autoﬂuorescence intensity patterns are classiﬁed in none
(no hyper-ﬂuorescence), focal, banded, patchy, and diffuse with
subgroups reticular, branching, ﬁne granular, trickling, and gran-
ular with peripheral punctuate spots (Bindewald et al., 2005).
Additionally, geographic atrophy can be classiﬁed in single and
multifocal lesions, and whether the foveal center is affected by
atrophy or spared (Bindewald et al., 2005).
Similarly, geographic atrophy can be investigated and classiﬁed
using autoﬂuorescence lifetime imaging (Dysli et al., 2016b,c,d)
(Fig. 10 B). Thereby, areas of RPE atrophy, appearing dark in auto-
ﬂuorescence intensity measurement due to missing auto-
ﬂuorescence contribution of the RPE, generally featured prolongedautoﬂuorescence lifetimes. However, a broad range of lifetime
values was detected, indicating contribution of different retinal
ﬂuorophores in the absence of the RPE. Long ﬂuorescence lifetimes
in geographic atrophy may originate from the underlying choroid
or from the inner retinal layers. In some cases, short ﬂuorescence
lifetimes were detected in the area of geographic atrophy in the
macular center. They presumably originate from the macular
pigment within the Henle ﬁber layer and were only found when
structures of the outer nuclear layer and outer plexiform layer were
partially preserved. Of special interest in advanced dry AMD are the
marginal zones of geographic atrophy. As known from auto-
ﬂuorescence intensity imaging, this zone helps to classify the
different forms of geographic atrophy and potentially provides in-
formation about disease progression. In FLIO, this border zone can
be demarcated and visualized using ﬂuorescence lifetimemaps and
2D correlation of the short and the long lifetime component.
Therefore, FLIO might be used for monitoring of progression of
geographic atrophy, and could serve as a tool for monitoring novel
treatment approaches for geographic atrophy involving comple-
ment factor inhibitors.
5.5.3. Neovascular age-related macular degeneration
Neovascular AMD is characterized by the presence of choroidal
neovascularization which are located below the RPE (type 1) or
above the RPE (type 2) (Yung et al., 2016). As the RPE and photo-
receptors are primarily intact, neovascularizations do not seem to
inﬂuence autoﬂuorescence intensity measurements in early dis-
ease stages. Over time, hypo-autoﬂuorescence can occur due to
blockage of RPE autoﬂuorescence by ﬁbrovascular complex and/or
progressive atrophy of the RPE and photoreceptors.
Fluorescence lifetime imaging in neovascular AMD revealed
generally slightly prolonged ﬂuorescence lifetimes (Fig. 11 C, Dysli
et al., 2016e). Local spots with prolonged lifetimes correlated
with intraretinal deposits or RPE atrophy. The presence or absence
or the amount of intraretinal ﬂuid did not signiﬁcantly inﬂuence
the measured mean ﬂuorescence lifetimes. Therefore, similar as in
post-acute disease stage in retinal artery occlusion, the inner retinal
layers and their distance from the RPE probably do not substantially
inﬂuence the measured mean ﬂuorescence lifetimes.
5.6. FLIO in diabetic retinopathy
Diabetic retinopathy is a micro-vascular complication in dia-
betes (Cogan and Kuwabara, 1963). Micro-vasculopathy and
inﬂammation ﬁnally result in neuronal degeneration (Barber et al.,
2011) and a breakdown of the blood e retina barrier causing reti-
nopathy and macular edema (Zhang et al., 2014). As hyperglycemia
is a primary event in diabetes, this causes not only an impairment of
the vascular endothelium but also a general protein glycation. This
formation of advanced glycation end products (AGE) in the non-
enzymatic Maillard reaction of proteins with glucose and other
sugar molecules is involved in blood e retina barrier breakdown
(Zhang et al., 2014) as well as endothelial dysfunction and activa-
tion of the protein kinase C pathway (Yu et al., 2001). AGE show
ﬂuorescence, and their concentration in serum was found to in-
crease with the severity of diabetic retinopathy (de la Maza et al.,
2012). As increased fundus autoﬂuorescence has been found in
diabetic macular edema in association with decreased macular
sensitivity (Vujosevic et al., 2011), Schweitzer et al (Schweitzer
et al., 2015). and Schmidt et al (Schmidt et al., 2017). investigated
fundus autoﬂuorescence lifetimes in diabetic patients.
Schweitzer et al (Schweitzer et al., 2015). compared the ﬂuo-
rescence lifetimes upon a 448 nm excitation for a group of 48 pa-
tients suffering from type two diabetes but no retinopathy with 48
healthy control subjects of same age. They found a general
Fig. 10. A) Autoﬂuorescence lifetimes in age-related macular degeneration with drusen. Areas of short respectively long ﬂuorescence lifetimes are shown in detail (adjusted color
scale). B) Autoﬂuorescence lifetimes in geographic atrophy (GA). a) Central geographic atrophy with 2D distribution histogram of the short (T1) versus the long (T2) decay
component. Thereby, borders of geographic atrophy can be identiﬁed. b) Geographic atrophy with foveal sparing. C) Autoﬂuorescence lifetimes in neovascular age-related macular
degeneration.
Fundus autoﬂuorescence intensity (FAF), ﬂuorescence lifetime (FLIO, LSC), OCT of the indicated green line in FAF image.
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Using a three-exponential ﬁt of the decay and a sophisticated sta-
tistical procedure, they revealed a good discrimination of both
groups with a sensitivity of 73% and 70% as well as a speciﬁcity of
84% and 64% for the two spectral channels used in this study
(490e560 nm and 560e700 nm) respectively for the mean ﬂuo-
rescence lifetime Tm. The best discrimination was achieved by the
intermediate lifetime component T2 at 490e560 nm (sensitivity
84%, speciﬁcity 76%) which the authors addressed to ﬂuorophores
in the retina. They discuss this as a result of reduced protein binding
of FAD as well as protein glycation leading to an accumulation ofAGEs. In a subgroup analysis, they found a considerably better
discrimination in phakic patients and controls as in pseudo-phakic.
Thus, they concluded an inﬂuence of the lens ﬂuorescence on the
measurements at the fundus despite the use of confocal scanning
due to the extremely strong ﬂuorescence emission from the lens. As
AGE accumulation in the lens is well known (Araki et al., 1992), this,
in part, could account for the lifetimes measured in diabetics.
Schmidt et al. (Schmidt et al., 2017) extended this study to pa-
tients with diabetic retinopathy. They compared ﬂuorescence life-
times upon excitation at 468 nm in 34 patients suffering from non-
proliferative diabetic retinopathy (NPDR) with that of 28 age
C. Dysli et al. / Progress in Retinal and Eye Research 60 (2017) 120e143136matched healthy controls. Fluorescence lifetimes were recorded in
the macular center as well as in two concentric rings given by the
standard ETDRS grid from a three-exponential ﬁt. Consistent with
Schweitzer et al., they showed prolonged lifetimes in the patient
group in all investigated retinal ﬁelds. This holds for both spectral
channels, however was more pronounced at short wavelengths
(498e560 nm, p  0.002) than for longer wavelengths
(560e700 nm, p < 0.05). A ROC (receiver operating characteristic)
analysis using a logistic regression model resulted in a sensitivity of
90% and a speciﬁcity of 71% for the discrimination of NPDR patients.
In contrast to Schweitzer et al., Schmidt et al. found the best
discrimination for the long-living ﬂuorescence component T3
instead of T2. This might result from the longer excitation wave-
length used. Again, the formation of AGEs in neurons, vascular, and
glial cells was discussed as source of the extension of lifetimes. This
was corroborated by FLIO measurements at the lenses of the sub-
jects. These showed shorter lifetimes in the patients, again pre-
dominantly in the short wavelength channel. As AGE (bovine serum
albumin incubated with glucose) showed a lifetime of 1.7 ns and an
emission maximum of 523 nm (Schweitzer et al., 2004),
(Schweitzer et al., 2007b) its accumulation must increase the
physiologically shorter fundus autoﬂuorescence lifetime, however
decrease that of the lens, which is known to be longer in healthy
state.
Taken together, investigations in diabetic patients indicated that
FLIO has the potential to show protein glycation as well asFig. 11. Autoﬂuorescence lifetimes in central serous chorioretinopathy (CSCR). A) Acute disea
and photoreceptor atrophy. C) Central area of acute disease activity characterized by short ﬂu
prolonged ﬂuorescence lifetimes. D) The 2D histogram of the short (T1) versus the long (
anatomical locations.
Fundus autoﬂuorescence intensity (FAF), ﬂuorescence lifetime (FLIO, LSC), OCT of the indicalterations in coenzymes of the cellular energy metabolism asso-
ciated with diabetes.
5.7. FLIO in central serous chorioretinopathy
Central serous chorioretinopathy (CSCR) is a macular disorder
characterized by idiopathic subretinal ﬂuid accumulation leading
to a decrease of visual acuity, metamorphopsia and micropsia. It
primarily affects males aged 40e51 years and is associated with the
use of corticosteroids and intrinsic cortisone metabolism
(Nicholson et al., 2013). This pathology affects both, the choroid and
the retina (Daruich et al., 2015). In the acute phase, leakage of ﬂuid
through the retinal pigment epithelium leads to serous retinal
detachment. Normally, the disease is self-limiting with sponta-
neous resorption of the ﬂuid. However, in over 50% central serous
chorioretinopathy can appear in a chronic form with persisting
subretinal ﬂuid of more than six months or in a chronic recurrent
form with periodical reappearance of ﬂuid (Nicholson et al., 2013).
So far, the exact disease mechanisms remain an area of active
investigation.
In a study of 35 patients (mean age 46 ± 6 years, range 29e53
years) FLIO was performed and lifetime values were analyzed in
different stages of disease (Fig. 11) (Dysli et al., 2017). Thereby, in
patients with reported onset of symptoms of less than six months,
shorter ﬂuorescence lifetimes were measured in affected areas
compared to age matched healthy controls (Dysli et al., 2017). These stage. B) Chronic recurrent disease stage with long ﬂuorescence lifetimes due to RPE
orescence lifetimes and temporal area of recent disease activity appearing with slightly
T2) decay component (from image C) shows speciﬁc lifetime clouds for the different
ated green line in FAF image.
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However, the short lifetimes correlated with the presence of
elongated outer segments of the photoreceptors (Dysli et al., 2017),
possibly due to accumulation of bisretinoids (visual cycle by-
products) such as all-trans-retinal dimer, A2PE, A2-DHP-PE and
A2-GPE (Sparrow et al., 2012) (Matsumoto et al., 2011). In physio-
logical conditions, the adjacent RPE degrades the shed outer
photoreceptor segments. Over time, the autoﬂuorescence lifetime
values prolong towards values of the unaffected retina (Dysli et al.,
2017). However, in chronic disease stage, secondary retinal changes
such as scar formation and retinal atrophy with loss of the RPE and
the photoreceptor layer lead towards longer lifetime values
compared to the mean autoﬂuorescence lifetime value of the
healthy retina. This correlates with data from FLIO measurements
in AMD with geographic atrophy. There, longer lifetimes were seen
in atrophic areas with absence of the RPE, and were assigned to
ﬂuorophores from connective tissue components such as collagen
and elastin (Dysli et al., 2017).
5.8. FLIO in Stargardt disease
Stargardt disease is the most common hereditary retinal dys-
trophy. The leading symptom is a progressive reduction of the
central visual acuity with onset in the second decade of life. The
underlying pathology is a mutation in the ABCA4 gene, which codes
for a receptor involved in the transport of vitamin A derivatives of
the visual cycle within the outer segments of the photoreceptors.
Due to this dysfunction, a progressive accumulation of byproducts
of the visual cycle, such as lipofuscin occurs within the RPE (Lewis
et al., 1999). The clinical manifestation varies widely due to a broad
phenotypic heterogeneity associated with a large number of ge-
netic sequence variants (Tanna et al., 2017). Typically, yellowish-
white deposits appear on the posterior pole of the retina. In later
stages, these deposits lead to a destruction of the RPE and the
retinal layer structure, and ﬁnally result in retinal atrophy. In
autoﬂuorescence intensity measurements, the retinal deposits
appear as hyperﬂuorescent spots compared to the surrounding
retina, which in general features increased autoﬂuorescence in-
tensity as found by quantitative autoﬂuorescence measurement
(Burke et al., 2014). In later stages, reduced autoﬂuorescence in-
tensity in atrophic areas was found due to absence of the RPE cell
layer (McBain et al., 2012).
In a study of 16 patients with Stargardt disease (mean age 40 ± 3
years, range 22e56 years) FLIO measurements were performed
(Dysli et al., 2016b,c,d) (Fig. 12). Autoﬂuorescence lifetimes within
areas of normal retinal layer structure without deposits or atrophy
was comparable to age matched healthy controls. Within hyper-
ﬂuorescent areas of retinal deposits corresponding to fundoscopi-
cally visible ﬂecks, shorter and longer ﬂuorescence lifetime values
compared to the normal retina were observed. In follow-up ex-
aminations, ﬂecks with initially short lifetimes were shown to
change to longer lifetimes, indicating a change of composition of
these deposits. By comparing in vivo data with ex vivo measure-
ments of intermediate compounds from the visual cycle, the short
autoﬂuorescence lifetime might be assigned to retinaldehyde ad-
ducts and bisretinoid ﬂuorophores located in degenerating photo-
receptor cells (Sparrow et al., 2015), whereas longer lifetimesmight
originate from photooxidation and photodegradation products of
A2E compounds. In individual cases, ﬂecks with short ﬂuorescence
lifetimes were visible in FLIO before they appeared as hyper-
ﬂuorescent deposits in the autoﬂuorescence intensity image.
FLIO provides a promising method to screen and follow-up pa-
tients with Stargardt disease and to monitor disease progression. In
late stage of disease, when retinal atrophy occurs, ﬂuorescence
lifetimes were prolonged in peripheral areas. However, within themacular center, remaining areas of short ﬂuorescence lifetimesmay
persist. This conﬁrms results from measurements in geographic
atrophy due to dry age related macular degeneration and is most
likely due to residual macular pigment.
By now, there is no therapy available for Stargardt disease.
However, novel experimental approaches include replacement of
vitamin A by deuterated vitamin A in order to inhibit vitamin A
dimerization and thereby formation of abnormal high amounts of
lipofuscin (Charbel Issa et al., 2015). First clinical studies are
ongoing and FLIO might be helpful to detect and quantify thera-
peutic efforts.
5.9. FLIO in choroideremia
Choroideremia is a rare hereditary retinal disease, affecting
mainly male subjects due to its X-linked inheritance pattern. This
monogenetic retinal dystrophy is caused by defects in the CHM
gene, which encodes Rab escort protein-1 (REP 1), a protein
responsible for membrane trafﬁcking in the retina and the RPE.
Choroideremia features a distinct phenotype and leads to pro-
gressive degeneration of well-deﬁned retinal layers such as the
choroid, the RPE, and the neurosensory retina (Zinkernagel and
MacLaren, 2015). Autoﬂuorescence intensity measurement in
choroideremia reveals distinctive patterns, whereby the area of
remaining autoﬂuorescence is inversely correlated with disease
progression (Jolly et al., 2016).
Using FLIO, areas of intact RPE were identiﬁed and visualized by
autoﬂuorescence intensity measurement (Fig. 13) (Dysli et al.,
2016b,c,d). Mainly due to the high content of lipofuscin, pre-
served RPE exhibited high level of autoﬂuorescence compared to
areas with RPE atrophy which appear dark in the intensity mea-
surement. In a study of 16 eyes of eight patients (mean age 55 ± 13
years, range 32e70 years) with advanced choroideremia, ﬂuores-
cence lifetime maps provided additional information in areas of
RPE atrophy (Dysli et al., 2016c). In areas with absence of the RPE,
regions with remaining photoreceptor layers in OCT were clearly
identiﬁable and featured shorter ﬂuorescence lifetimes compared
to areas with combined RPE- and photoreceptor loss. These short
lifetimes might origin from remaining visual cycle activity within
the persisting photoreceptors segments with generation and
accumulation of visual cycle by-products (e.g. all-trans-retinal di-
mers with short ﬂuorescence lifetimes) (Goldberg et al., 2016).
In FLIO, retinal areas with complete chorioretinal atrophy
featured the longest mean ﬂorescence lifetimes, and areas of intact
retinal layer structure within the macular center featured the
shortest lifetimes (Dysli et al., 2016c). In follow-up examinations, a
decrease of short ﬂuorescence lifetimes was correlated with dis-
ease progression and increase of chorioretinal atrophy (Dysli et al.,
2016c). Using 2D correlations of the short decay component T1
versus the long component T2, distribution and borders of indi-
vidual areas were clearly separable (Dysli et al., 2016c).
6. FLIO in mouse models
With the development and presence of numerous animal
models for nearly all ophthalmic and systemic diseases and con-
ditions, in vivo imaging in animal models has become more and
more important within the last decades. Animal models are used to
mimic various diseases in order to investigate the pathophysio-
logical pathways involved, the natural course of disease, and po-
tential therapeutic interventions. Therefore, ophthalmic imaging
techniques such as OCT, ﬂuorescein angiography, and auto-
ﬂuorescence intensity measurement were adapted and modiﬁed
for retinal imaging in small rodents.
We adapted the FLIO technique for the use in mice and
Fig. 12. Autoﬂuorescence lifetimes in Stargardt disease. Retinal deposits with short and long ﬂuorescence lifetimes are discernible and identiﬁable on the 2D distribution histogram.
Fundus autoﬂuorescence intensity (FAF), ﬂuorescence lifetime (FLIO, LSC), OCT of the indicated green line in FAF image.
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albino BALBc mice. Fluorescence lifetimes were shown to be
shorter in non-pigmented retinae compared to C57BL/6 mice
(Fig. 14) (Dysli et al., 2014a; Dysli et al., 2016a). Possibly, retinal
melanin might contribute to longer ﬂuorescence lifetimes in pig-
mented mice. In the short spectral channel, ﬂuorescence lifetimes
in the murine retina were on average 800e950 ps and therefore
signiﬁcantly longer than those observed in the human retina and
signiﬁcantly longer than the lifetime values reported for lipofuscin
(390 ps). In the long spectral channel, similar values were
measured. Over the observational period of seven months, in all
mouse models a trend towards shorter lifetimes was observed in
both spectral channels. A possible explanation is that over time and
with progressive accumulation of retinal ﬂuorophores, such as
lipofuscin, the mean lifetime shortens in the murine retina and
prolongs in human eyes, and thereby approaches similar values. In
contrast to the human retina, murine retinal vessels featured
signiﬁcantly shorter lifetime values compared to the surrounding
retina.
In a mouse model of slow retinal degeneration (short RDS,
C3A.Cg-Pde6bþPrph2Rd2/J) there was a marked variance of lifetimeFig. 13. Autoﬂuorescence lifetimes in choroideremia. Hyperﬂuorescent areas in FAF corresp
partially intact photoreceptor layer structure. Corresponding 2D histogram is shown.
Fundus autoﬂuorescence intensity (FAF), ﬂuorescence lifetime (FLIO, LSC), OCT of the indicvalues in animals within the same age group. RDS mice feature a
slow degeneration of the outer nuclear layer, primarily the rod,
followed by the cone cells, and ﬁnally degeneration of all retinal
layers including the retinal pigment epithelium (Schalken et al.,
1990; Dysli et al., 2014a). In this model, patchy changes of retinal
lifetime values were observed, resulting most likely from different
stages of degeneration within the same retina.
In order to investigate the contribution of individual retinal
layers to the measured autoﬂuorescence lifetime, pharmacological
degeneration of speciﬁc layers was induced in C57BL/6 mice (Dysli
et al., 2014a; Dysli et al., 2016a). A well suited model to study the
inﬂuence of individual retinal layers is the sodium iodate (NaIO3)
induced model of retinal degeneration, which primarily leads to
degeneration of the RPE, followed by subsequent loss of photore-
ceptors. Over the experiment duration of one month, a prolonga-
tion of retinal autoﬂuorescence lifetimes was observed. In another
model, N-methyl-N-nitrosourea (MNU) was used for speciﬁc
ablation of the photoreceptor cell layer with preservation of the
RPE. Here, a shortening of the mean autoﬂuorescence lifetime
values was observed. Short autoﬂuorescence lifetimes in the mu-
rine retina may mainly originate from the RPE and may beond to remaining islands of RPE. Shorter ﬂuorescence lifetimes correlate with areas of
ated green line in FAF image.
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autoﬂuorescence lifetimes. In case of photoreceptor degeneration,
the contribution of short ﬂuorescence lifetimes from the RPE is
increased, probably due to missing attenuation of overlying pho-
toreceptors and/or due to increased RPE activity caused by addi-
tional cell debris from degenerating photoreceptors. On the other
hand, if the RPE is destroyed, metabolic activity of this layer is also
extinct and long ﬂuorescence lifetimes from other layers such as
the choroid or the inner retinal layers might dominate the
measured mean ﬂuorescence lifetime.
Overall, ﬂuorescence lifetime imaging in mouse models pro-
vides an interesting tool to record and investigate metabolic
changes in speciﬁc and well deﬁned metabolic or genetic
conditions.7. Conclusion and future directions
Autoﬂuorescence lifetime imaging ophthalmology is a novel
imaging technology which provides additional insights into meta-
bolic processes of the retina. As illustrated in this review, FLIO is
based on measurement of decay times of intrinsic ﬂuorescence.
Fluorescence lifetime imaging in ophthalmology has been shown to
be highly reproducible and provides distinct and speciﬁc infor-
mation for different retinal diseases.
In combination with common standard imaging techniques
such as color fundus photography and optical coherence tomog-
raphy, the FLIO technique provides additional information on
structural alterations in retinal diseases. Various applications of
FLIO measurements are summarized in this review, ranging from
vascular disorders over degenerative diseases and age related
changes to hereditary retinal diseases. Retinal autoﬂuorescence
lifetime images and individual lifetime values can be analyzed
both, in a qualitative and quantitative way. Basic information is
provided in the mean lifetime value Tm, representing the ampli-
tude weighted mean ﬂuorescence lifetime value. Tm is currently
regarded as the main outcome parameter in FLIO, representing the
most important lifetime information. The color coded TmFig. 14. Autoﬂuorescence lifetimes in mice. Fundus autoﬂuorescence intensity (FAF)
and lifetime maps (FLIO) of pigmented C57BL/6 mice (A) and non pigmented BALBc
mice (B) (short spectral channel). Note the different color range (500e1400 ps).histograms of ﬂuorescence lifetime measurements provide an
easy overview of lifetime changes in the retina. However, analysis
of individual lifetime components and 2D histograms are more
complex to analyze and at this stage probably not suitable for
everyday clinical use. Additionally, the technique allows for
reﬁned analysis and visualization of individual lifetime compo-
nents depending on the scientiﬁc question. Follow-up examina-
tions as well as versatile opportunities to analyze, investigate, and
present the acquired lifetime data enable further clinical and
research opportunities.
FLIO measurement of single compounds, solutions, cell cultures
and mouse models might provide essential information for dis-
secting the fraction of individual ﬂuorophores within the obtained
ﬂuorescence lifetime signal.
Currently, the provided information is based on individual pilot
studies. Further studies will reﬁne and expand the current
knowledge, and investigate subtle retinal changes over time in
order to identify ﬂuorescence lifetime biomarkers for retinal dis-
ease. Similar to fundus autoﬂuorescence intensity imaging, FLIO is
mainly a qualitative imaging procedure. However, as shown in this
review, it has the potential to be analyzed quantitatively using the
ﬂuorescence lifetime values. This enables and facilitates standard-
ized imaging procedure for data comparison between individual
subjects, diseases and for follow-up examinations over time.
Additional efforts in expanded translational possibilities from
in vitro to in vivo will further improve the understanding of retinal
autoﬂuorescence lifetimes in physiological conditions and meta-
bolic changes. It is important to be aware of certain limitations
when using this technique. Despite the confocality of the FLIO
system, the lifetime signal obtained in any given pixel represents a
bulk signal from various adjacent ﬂuorophores. Additionally,
contribution of components from other structures such as the
cornea and the lens cannot be entirely excluded. Furthermore, as
with other imaging modalities, there is a certain degree of variation
between individual subjects and variation with age.
In future applications FLIO might serve as a tool for visualization
of early retinal changes in hereditary retinal dystrophies as shown
for Stargardt disease and choroideremia, and therefore may be
invaluable to test novel therapeutic approaches such as gene
therapy. In addition, follow-up examinations with FLIO in heredi-
tary as well as degenerative retinal diseases such as dry age-related
macular degeneration could provide information on therapeutic
effects in respective trials. Further studies will show the value of
this method for detection of early systemic metabolic conditions
such as elevated blood glucoses like in pre-diabetic conditions,
dyslipidemia and neurodegenerative diseases by analysis of the
retinal autoﬂuorescence lifetimes.
For future approaches, the basic FLIO device might be reﬁned
and could include adjustable autoﬂuorescence excitation wave-
lengths and range of detection for emitted ﬂuorescence. Thereby
individual ﬂuorophores could be addressed more speciﬁcally. Also
analysis of the registered ﬂuorescence lifetimes could be reﬁned
and interpretation could be standardized and automated.
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